Down-regulation of osteopontin attenuates breast tumour progression in vivo

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 6A, 2008, Pages 2305-2318

  Chakraborty, Goutam ^a   Jain, Shalini ^a   Patil, Tushar V ^b   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b YCM Hospital   (India)

Author keywords

Angiogenesis; Breast tumour progression; Osteopontin; Pristane

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PRISTANE; SMALL INTERFERING RNA; SPP1 PROTEIN, MOUSE; TERPENE; UROKINASE; VON WILLEBRAND FACTOR;

ANIMAL; ARTICLE; BREAST TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CELL MOTION; CHEMICALLY INDUCED DISORDER; DOWN REGULATION; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OSTEOPONTIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TERPENES; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

MUS;

EID: 49549089944     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00263.x     Document Type: Article

References (47)

1. Chatterjee SK, Zetter BR. Cancer bio-markers: knowing the present and predicting the future. Future Oncol. 2005 1 : 37 50.
2. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006 16 : 79 87.
3. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. CurrMolMed. 2006 6 : 819 30.
4. Higashibata Y, Sakuma T, Kawahata H, Fujihara S, Moriyama K, Okada A, Yasui T, Kohri K, Kitamura Y, Nomura S. Identification of promoter regions involved in cell- and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice. J Bone Miner Res. 2004 19 : 78 88.
5. Takahashi F, Takahashi K, Shimizu K, Cui R, Tada N, Takahashi H, Soma S, Yoshioka M, Fukuchi Y. Osteopontin is strongly expressed by alveolar macrophages in the lungs of acute respiratory distress syndrome. Lung. 2004 182 : 173 85.
6. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003 198 : 107 17.
7. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin induced PKCα/c-Src/IKKα/β dependent prostate tumor progression and angiogenesis. Cancer Res. 2006 66 : 6638 48.
8. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carclnog. 2005 43 : 225 36.
9. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006 25 : 2192 202.
10. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001 6 : 419 29.
11. Adwan H, Bauerle TJ, Berger MR. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther. 2004 11 : 109 20.
12. Suva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets. 2004 4 : 327 36.
13. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. Mammary Gland Biol Neoplasia. 2003 8 : 215 23.
14. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P, Cabon F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limitstumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003 63 : 3919 22.
15. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004 64 : 3365 70.
16. Kang CS, Zhang ZY, Jia ZF, Wang GX, Qiu MZ, Zhou HX, Yu SZ, Chang J, Jiang H, Pu PY. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. Cancer Gene Ther. 2006 13 : 530 8.
17. Pu P, Liu X, Liu A, Cui J, Zhang Y. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. JNeurosurg. 2000 92 : 132 9.
18. Ait-Si-Ali S, Guasconi V, Harel-Bellan A. RNA interference and its possible use in cancer therapy. Bull Cancer. 2004 91 : 15 8.
19. Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis. 2003 20 77 84.
20. Ohyama Y, Nemoto H, Rittling S, Tsuji K, Amagasa T, Denhardt DT, Nifuji A, Noda M. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res. 2004 19 : 1706 11.
21. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, Chang PL. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006 66 : 7119 27.
22. Banbura M, Ackland-Berglund C, Lee SH, Hamernik D, Jones C. Analysis of transcriptional activation of a cyclic AMP response element by 2,6,10,14-tetramethylpentadecane (pristane) in JB6 mouse epidermal cells. Mol Carcinog. 1994 11 : 204 14.
23. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 1969 222 : 994 5.
24. Armstrong MY, Ebenstein P, Konigsberg WH, Richards FF. Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas. Proc Natl Acad Sci USA. 1978 75 : 4549 52.
25. Janz S, Gawrisch K, Lester DS. Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane. Cancer Res. 1995 55 : 518 24.
26. Horton AW, Bolewicz LC, Barstad AW, Butts CK. Comparison of the promoting activity of pristane and n-alkanes in skin carcinogenesis with their physical effects on micellar models of biological membranes. Biochim Biophys Ada. 1981 648 : 107 12.
27. Udayachander M, Meenakshi A, Krishnan RH, Padma S, Velvizhi R. Immunoscintigraphy of MCF7 rat mammary tumour xenograft using monoclonal antibody. Indian J Biochem Biophys. 1994 31 : 31 5.
28. Ohno S. Chromosome translocations and the activation of C-myc oncogene in mouse plasmacytomas. Gan To Kagaku Ryoho. 1984 11 : 587 96.
29. Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J Leukoc Biol. 2004 76 : 227 36.
30. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B- mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001 276 : 44926 35.
31. Hazama A, Fan HT, Abdullaev I, Maeno E, Tanaka S, Ando-Akatsuka Y, Okada Y, Swelling-activated, cystic fibrosis trans-membrane conductance regulator-augmented ATP release and Cl- conductances in murine C127 cells. J Physiol. 2000 523 : 1 11.
32. Sclimenti CR, Baba EJ, Calos MP. An extrachromosomal tetracycline- regulatable system for mammalian cells. Nucleic Acids Res. 2000 28 : e80.
33. Teramoto H, Castellone MD, Malek RL, Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV1 2. Oncogene. 2005 24 : 489 501.
34. Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between syk and Ick leading to breast cancer progression and angiogenesis. J Biol Chem. 2006 281 : 11322 31.
35. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003 278 : 14487 97.
36. Gillespie DL, Whang K, Ragel BT, Flynn JR, Kwlly DA, Jensen RL. Silencing of hypoxia inucible factor-1a by RNA interference attenuates hman glioma cell growth in vivo. Clin Cancer Res. 2007 13 : 2441 8.
37. Garcia FU, Urbanska K, Koltowski L, Reiss K, Sell C. Insulin-like growth factor-i produced by seminal vesicles: relationship to intraepithelial basal cell hyperplasia in the prostate. Clin Cancer Res. 2007 13 : 3140 6.
38. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of his-tologic grade to improve prognosis. J Natl Cancer Inst. 2006 98 : 262 72.
39. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005 353 : 1564 73.
40. Dolle L, Depypere HT, Bracke ME. Anti-invasive/anti-metastasis strategies: new roads, new tools and new hopes. Curr Cancer Drug Targets. 2006 6 : 729 51.
41. Moore S, Cobleigh MA. Targeting metastatic and advanced breast cancer. Semin Oncol Nurs. 2007 23 : 37 45.
42. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007 6 : 273 86.
43. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets. 2007 11 : 81 90.
44. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes VEGF dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008 68 : 152 61.
45. Cogliano VJ, Grosse Y, Baan RA Straif K, Secretan MB, El Ghissassi F Working Group for Volume 88. Meeting report: summary of IARC monographs on formaldehyde, 2-butoxyethanol, and 1-tert-butoxy-2-propanol. Environ Health Perspect. 2005 113 : 1205 8.
46. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res. 2001 16 : 652 9.
47. Natasha T, Kuhn M, Kelly O., Rittling SR. Override of the osteoclast defect in osteo-pontindeficient mice by metastatic tumor growth in the bone. Am J Pathol. 2006 168 : 551 61.